5BJT

Crystal structure of human FcRn with a peptide inhibitor at multiple sites


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.339 
  • R-Value Work: 0.252 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.

Pyzik, M.Rath, T.Kuo, T.T.Win, S.Baker, K.Hubbard, J.J.Grenha, R.Gandhi, A.Kramer, T.D.Mezo, A.R.Taylor, Z.S.McDonnell, K.Nienaber, V.Andersen, J.T.Mizoguchi, A.Blumberg, L.Purohit, S.Jones, S.D.Christianson, G.Lencer, W.I.Sandlie, I.Kaplowitz, N.Roopenian, D.C.Blumberg, R.S.

(2017) Proc. Natl. Acad. Sci. U.S.A. 114: E2862-E2871

  • DOI: 10.1073/pnas.1618291114

  • PubMed Abstract: 
  • The neonatal crystallizable fragment receptor (FcRn) is responsible for maintaining the long half-life and high levels of the two most abundant circulating proteins, albumin and IgG. In the latter case, the protective mechanism derives from FcRn bind ...

    The neonatal crystallizable fragment receptor (FcRn) is responsible for maintaining the long half-life and high levels of the two most abundant circulating proteins, albumin and IgG. In the latter case, the protective mechanism derives from FcRn binding to IgG in the weakly acidic environment contained within endosomes of hematopoietic and parenchymal cells, whereupon IgG is diverted from degradation in lysosomes and is recycled. The cellular location and mechanism by which FcRn protects albumin are partially understood. Here we demonstrate that mice with global or liver-specific FcRn deletion exhibit hypoalbuminemia, albumin loss into the bile, and increased albumin levels in the hepatocyte. In vitro models with polarized cells illustrate that FcRn mediates basal recycling and bidirectional transcytosis of albumin and uniquely determines the physiologic release of newly synthesized albumin into the basal milieu. These properties allow hepatic FcRn to mediate albumin delivery and maintenance in the circulation, but they also enhance sensitivity to the albumin-bound hepatotoxin, acetaminophen (APAP). As such, global or liver-specific deletion of FcRn results in resistance to APAP-induced liver injury through increased albumin loss into the bile and increased intracellular albumin scavenging of reactive oxygen species. Further, protection from injury is achieved by pharmacologic blockade of FcRn-albumin interactions with monoclonal antibodies or peptide mimetics, which cause hypoalbuminemia, biliary loss of albumin, and increased intracellular accumulation of albumin in the hepatocyte. Together, these studies demonstrate that the main function of hepatic FcRn is to direct albumin into the circulation, thereby also increasing hepatocyte sensitivity to toxicity.


    Organizational Affiliation

    Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.,Division of Gastroenterology and Nutrition, Children's Hospital Boston, Boston, MA 02115.,Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, MA 02114.,Department of Biosciences, University of Oslo, Oslo 0316, Norway.,Department of Pediatrics, Harvard Medical School, Boston, MA 02115.,Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033.,Department of Immunology, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo 0424, Norway.,Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; rblumberg@bwh.harvard.edu.,The Jackson Laboratory, Bar Harbor, ME 04609.,Molecular Pathology Unit, Massachusetts General Hospital, Charlestown 02129 MA.,Zenobia Therapeutics, Inc., San Diego, CA 92121.,Department of Pathology, Harvard Medical School, Boston 02115 MA.,Syntimmune Inc., New York, NY 10010.,Biogen Idec-Hemophilia, Inc., Waltham, MA 02451.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
IgG receptor FcRn large subunit p51
A, C, E, G
267Homo sapiensMutation(s): 0 
Gene Names: FCGRT (FCRN)
Find proteins for P55899 (Homo sapiens)
Go to Gene View: FCGRT
Go to UniProtKB:  P55899
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Beta-2-microglobulin
B, D, F, H
99Homo sapiensMutation(s): 0 
Gene Names: B2M
Find proteins for P61769 (Homo sapiens)
Go to Gene View: B2M
Go to UniProtKB:  P61769
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
peptide inhibitor
P, Q, R, S, T, U, V
19N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
NH2
Query on NH2
P, Q, R, S, T, U, V
NON-POLYMERH2 N

--

ACE
Query on ACE
P, Q, R, S, T, U, V
NON-POLYMERC2 H4 O

--

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.339 
  • R-Value Work: 0.252 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 104.917α = 90.00
b = 176.152β = 90.00
c = 245.515γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data reduction
HKL-2000data scaling
REFMACrefinement
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2017-03-22
    Type: Initial release
  • Version 1.1: 2017-04-05
    Type: Database references
  • Version 1.2: 2017-04-19
    Type: Database references